¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾çÇÐȸ 2019 KGOG Winter Workshop Ovarian Cancer : 2019-02-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾çÇÐȸ 2019 KGOG Winter Workshop Ovarian Cancer : 2019-02-17
±³À°ÀÏÀÚ : 2019-02-17
±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ´ë°­´ç  
±³À°ÁÖÁ¦ : 2019 KGOG Winter Workshop Ovarian Cancer
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸  
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420  
À̸ÞÀÏ : koreagynonco@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 35ºÐ  
¼¼ºÎ¼ö°­·á : 30,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 08:55~09:00 Orientation  °­¼®¹ü(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:00~09:15 Review of ESMO-ESGO consensus guideline of ovarian cancer  ÃÖÇöÁø(Á߾Ӵ뺴¿ø) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:15~09:30 2018 Best international research paper on ovarian cancer  ¼ÛÅÂÁ¾(°­ºÏ»ï¼ºº´¿ø) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:30~09:45 2018 Best Korean research paper on ovarian cancer  ¹èÀ縸(ÇѾç´ëº´¿ø) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:45~09:55 Discussion  () 
È޽Ġ02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 09:55~10:15 Coffee Break  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 10:15~10:45 How can we provide optimal treatment outcome for BRCA mutation OC patients?  Áö¿ëÀÏ(ÇØ¿î´ë¹éº´¿ø) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 10:45~11:15 How can we conduct early testing and high quality testing of BRCA mutation?  ¼ºÃ¢¿Á(¼­¿ï¾Æ»êº´¿ø) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:15~11:25 Discussion  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:25~11:55 IO Drug adverse event overview  ¼±Á¾¹«(»ï¼º¼­¿ïº´¿ø) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 11:55~12:05 Discussion  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 12:05~12:15 Case 1  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 12:15~12:25 Case 2  ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 12:25~12:35 Discussion  () 
½Ä»ç 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 12:35~13:30 Lunch  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 13:30~13:45 Hormone treatment in ovarian cancer (OV 1607)  À̹æÇö(°­µ¿¼º½Éº´¿ø) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 13:45~14:00 HIPEC for platinum sensitive recurrent EOC (OV 1603)  ±èÈñ½Â(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:00~14:15 Minimally invasive surgery in ovarian cancer (OV 1610)  ¹é¹ÎÇö(ÇѸ²´ë¼º½Éº´¿ø) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:15~14:25 Discussion  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:25~14:45 Perspective of individualized molecularly targeted therapy of ovarian cancer based on genomic profile  noriomi Matsumura(Kinki University Japan) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 14:45~15:05 Genomic/epigenomic characterization of high grade serous ovarian carcinoma, leading to an investigator-initiated phase 2 clinical trial on basis of NGS-based biomarker  Katsutoshi Oda(Tokyo University Japan) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:05~15:15 Discussion  () 
È޽Ġ02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:15~15:35 Coffee Break  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:35~15:50 ³­¼Ò¾Ï Ä¡·á¿ë Â÷¼¼´ë¼öÁö»ó¼¼Æ÷ Ç׾Ϲé½Å  ÀÌÇö¾Æ(ÆĹ̼¿) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 15:50~16:00 Discussion  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:00~16:15 Oncolytic virus immunotherapy: Pexa-Vec and its place in the Immuno-Oncology combination regimens  ±ÇÇõÂù(½Å¶óÁ¨) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:15~16:25 Discussion  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:25~16:40 Development of anti-PD-L1, immuno-oncology antibody, KL001-13  ±è´ëÈñ(½ºÅ©¸³½ºÄÚ¸®¾ÆÇ×ü¿¬±¸¿ø) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:40~16:50 Discussion  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 16:50~17:05 Thoracic Radiation in EOC  ±è¼¼ÀÍ(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:05~17:15 Discussion  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:15~17:30 Proper Treatment of Incidental Immature Teratoma G1  ¿À¿µÅÃ(°í´ë±¸·Îº´¿ø) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:30~17:40 Discussion  () 
±³À°½Ã°£ 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:40~17:55 PembrolizumabÀÇ Ä¡·á È¿°ú ¿¹ÃøÀ» À§ÇÑ biomarker Ž»ö  Á¶ÀçÇö(¼­¿ï´ëº´¿ø) 
Åä·Ð 02-17 ¼­¿ï¾Æ»êº´¿ø¿¬±¸¿øÁöÇÏ´ë°­´ç 17:55~18:05 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï¾Æ»êº´¿ø ´ëÇѺÎÀÎÁ¾¾çÇÐȸ 2019 KGOG Winter Workshop Ovarian Cancer : 2019-02-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï¾Æ»êº´¿ø The 3rd AMC Pain Clinic Cadaver WORKSHOP : 2019-02-17
´ÙÀ½±Û Á¦55ȸ ´ëÇÑ°©»ó¼±µÎ°æºÎ¿Ü°úÇÐȸ µ¿°èÇмú´ëȸ : 2019-02-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 81 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 44 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 53 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 57 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 50 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 47 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 23 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 18 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 46 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 23 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 18 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 53 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 31 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 39 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 33 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷